Stockreport

Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026 [Yahoo! Finance]

MiNK Therapeutics, Inc.  (INKT) 
PDF Data expected to inform immune modulation, treatment sequencing, and durability of response across hard-to-treat tumors LEXINGTON, Mass., April 03, 2026 BUSINESS WIRE [Read more]